Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1987-04-03
1990-10-23
Moskowitz, Margaret
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 21, 530350, 530380, 530395, A61K 3702
Patent
active
049652516
ABSTRACT:
A method of treating a hemoglobinopathic condition such as sickle cell anemia, by pulse treatment with erythropoietin. In one embodiment, each of one or more treatment regimens includes a first time period during which erythropoietin is administered to a hemoglobinopathic patient and a second time period during which erythropoietin is withheld from the patient. During the first time period, sufficient erythropoietin is administered to increase F-reticulocyte formation in the patient. The pulse treatment preferably includes a plurality of the treatment regimens, in which case the durations of the second time periods are selected to achieve a cumulative increment of F-cell count sufficient to effectively treat the patient'
REFERENCES:
patent: 3865801 (1975-02-01), Chiba et al.
patent: 4303650 (1981-12-01), Takezawa et al.
patent: 4397840 (1983-08-01), Takezawa et al.
patent: 4568488 (1986-02-01), Lee-Huang
patent: 4677195 (1987-06-01), Hewick et al.
patent: 4703008 (1987-10-01), Lin
Essers et al., Proc. Eur. Dial. Transplant Ass'n, 11, 398-402, (1974).
Papayannopoulou, Th., et al., Fetal Hb production during acute erythroid expansion, Br. J. Haemat 44:535-546, 1980.
Alter, B.A., Fetal erythropoiesis in bone marrow failure syndromes, in Cellular and Molecular Regulation of Hemoglobin Switching, G. Stamatoyannopoulos and A. W. Nienhuis, Eds., Grune and Stratton, N.Y., pp. 87-105, 1979.
Dover, G. J., et al., Production of erythrocytes that contain fetal hemoglobin in anemia: transient in vivo changes, J. Clin. Invest. 63:173-176, 1979.
Desimone, J., et al., Stimulation of fetal hemoglobin synthesis in baboons by hemolysis and hypoxia, Proc. Natl. Acad. Sci. (USA) 75(6):2937-2940, 1978.
Nute, P. E., et al., Acceleration of F--cell production in response to experimentally induced anemia in adult baboons (Papio cynocephalus), Am. J. Hematal. 8:157-168, 1980.
Dover, C. J., et al., Progress toward incresing fetal hemoglobin production in man: experience with 5--azacytidine and hydroxyurea, Ann. N.Y. Acad. Sci. 445:218-224, 1985.
Stamatoyannopoulos, G., and A. W. Nienhuis, Hemoglobin switching, in The Molecular Basis of Blood Diseases, G. Stamatoyannopoulos, et al., Eds., W. B. Saunders Company, pp. 66-105, 1987.
McGonigle et al., Kidney, Int., 25, 437-44, (1984).
Pavlovic-Kentera et al., Biol. Abs., 73(1), p. 62, Abs. 587, (1982)
Eschbach et al., J. Clin. Invest., 74, 434-41, (1984).
Egrie et al., Biol. Abs., 83(5), p. Ab. 317, Abs. #92648, (1986 (pub. date)).
Stamatoyannopoulos, G., and Th. Papayannopoulou, Fetal hemoglobin and the erythroid stem cell differentiation process, in Cellular and Molecular Regulation of Hemoglobin Switching, G. Stamatoyannopoulous and A. W. Nienhuis, Eds., Grune & Stratton, New York, pp. 323-350, 1979.
Stamatoyannopoulos, G., et al., Hb F production in stressed erythropoiesis: observations and kinetic models, Ann. N.Y. Acad. Sci. 445:188-197, 1985.
DeSimone, J., et al., 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons, Proc. Natl. Acad. Sci. (USA) 79:4428-4431, 1982.
Torrealba--de Ron, A. T., et al., Perturbations in the erythroid marrow progenitor cell pools may play a role in the augmentation of HbF by 5--azacytidine, Blood 63(1):201-210, 1984.
Ley, T. J., et al., 5--Azacytidine selectively increases gammaglobin synthesis in a patient with beta+ thalassemia, N. Engl. J. Med. 307(24):1469-1475, 1982.
Ley, T. J., et al., 5--Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia, Blood 62(2):370-380, 1983.
Nienhuis, A. W., et al., Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe beta--Thalassemia, Ann. N.Y. Acad. Sci. 445:198-211, 1985.
Charache, S., et al., Treatment of sickle cell anemia with 5--azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-globin gene complex, Proc. Natl. Acad. Sci. (USA) 80:4842-4846, 1983.
Humphries, R. K., et al., 5--Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin, J. Clin. Invest. 75:547-557, 1985.
Dover, G. J., et al., 5--Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose--response analysis of subcutaneous and oral dosage regimens, Blood 66(3):527-532, 1985.
Papayannopoulou, Th., et al., Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics, Science 224:617-619, 1984.
Letvin, N. L., et al., Augmentation of fetal--hemoglobin production in anemic monkeys by hydroxyurea, New Engl. J. Med. 310(14):869-873, 1984.
Platt, O. S., et al., Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia, J. Clin. Invest. 74:652-656, 1984.
Veith, R., et al., Stimulation of F--cell production in patients with sickle--cell anemia treated with cytarabine or hydroxyurea, N. Engl. J. Med. 313(25):1571-1575, 1985.
Dover, G. J., et al., Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production, Blood 67(3):735-738, 1986.
Charache, S., et al., Hydroxyurea--induced augmentation of fetal hemoglobin production in patients with sickle cell anemia, Blood 69(1):109-116, 1987.
Veith, R., et al., Treatment of baboon with vinblastine: insights into the mechanisms of pharmacologic stimulation of HbF in the adult, Blood 66(2):456-459, 1985.
Spivak, J. L., The mechanisms of action of erythropoietin, Intl. J. Cell Cloning 4:139-166, 1986.
Papayannopoulou, Th., et al., On the in vivo action of erythripoietin: quantative analysis, J. Clin. Invest. 51:1179-1185, 1972.
Papayannopoulou, Th., et al., Hemoglobin F synthesis in vitro: evidence for control at the level of primitive erythroid stem cells, Proc. Natl. Acad. Sci. (USA) 74(7):2923-2927, 1977.
Macklis, R. M., et al., Synthesis of hemoglobin F in adult simian erythroid progenitor--derived colonies, J. Clin. Invest. 70:752-761, 1982.
Torrealba de Ron, A., et al., Studies of HbF in adult non--anemic baboons: HbF expression in erythroid colonies decreases as the level of maturation of erythroid progenitors advances, Exp. Hematol. 13:919-925, 1985.
Adamson, J. W., et al., Activation of hemoglobin C synthesis in sheep marrow culture, Science 180:310-312, 1973.
Nienhuis, A. W., et al., Induction of hemoglobin C synthesis in sheep: characterization of the "switching" stem cell, in Cellular and Molecular Regulation of Hemoglobin Switching, G. Stamatoyannopoulos and A. W. Nienhuis, Eds., Grune & Stratton, New York, pp. 397-420, 1978.
Papayannopoulou, Th., et al., Cellular regulation of hemoglobin switching: evidence for inverse relationship between fetal hemoglobin synthesis and degree of maturity of human erythroid cells, Proc. Natl. Acad. Sci. (USA) 76(12):6420-6424, 1979.
Eschbach, J. W., et al., Correction of the anemia of end--stage renal disease with recombinant human erythropoietin, N. Eng. J. Med. 316(2):73-78, Jan. 1987.
Winearls, C. G., et al., Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis, The Lancet ii:1175-1178, Nov. 1986.
Alter, B. P., et al., Fetal erythropoiesis following bone marrow transplantation, Blood 48():843-852, 1976.
Amylon et al., Am. J. Hematol,, 23, 179-81, (1986).
Kushan Jeff
Moskowitz Margaret
The Board of Regents of the University of Washington
LandOfFree
Pulse treatment of hemoglobinopathies with erythropoietin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pulse treatment of hemoglobinopathies with erythropoietin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pulse treatment of hemoglobinopathies with erythropoietin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-766941